PI3K-mTOR in Cancer and Cancer Therapy

  • Nandini Dey
  • Pradip De
  • Brian Leyland-Jones

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xxiv
  2. Sameer S. Chopra, Lewis C. Cantley
    Pages 1-25
  3. PI3K-mTOR Pathway in Cancers

    1. Front Matter
      Pages 27-27
    2. Thomas Lynch, Joseph G. Moloughney, Estela Jacinto
      Pages 29-63
    3. John Conor Moran, Elisa Baldelli, Emanuel F. Petricoin, Mariaelena Pierobon
      Pages 109-124
    4. Payal D. Shah, Sarat Chandarlapaty
      Pages 125-147
  4. PI3K-mTOR Pathway in Cancer Medicine

    1. Front Matter
      Pages 149-149
    2. Aung Naing, Gordon B Mills, Funda Meric-Bernstam
      Pages 151-180
    3. Nandini Dey, Brian Leyland-Jones, Pradip De
      Pages 231-261
  5. Back Matter
    Pages 291-294

About this book


In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance.   Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.​


apoptosis cancer cancer metabolism drug development drug resistance signaling pathway

Editors and affiliations

  • Nandini Dey
    • 1
  • Pradip De
    • 2
  • Brian Leyland-Jones
    • 3
  1. 1.Oncology, Head of Cancer BiologyAvera Cancer Instit Center for PrecisionSIOUX FALLSUSA
  2. 2.Oncology, Head of Translational OncologyAvera Cancer Institute Center for PreciSioux FallsUSA
  3. 3.Precision Oncology,Avera Cancer Institute Center forSioux FallsUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media New York 2016
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-34209-2
  • Online ISBN 978-3-319-34211-5
  • Series Print ISSN 2196-9906
  • Series Online ISSN 2196-9914
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology